Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus TRI MILI.
DASETTA 1/35 vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive